Integra Therapeutics, a Barcelona, Spain-based biotechnology company that creates next- generation gene writing tools, raised an additional €1.5m in seed funding.
Columbus Venture Partners (Columbus Life Science Fund III FCR) made the investment, which follows a €4.5m Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures. In conjunction with the funding. Damià Tormo, managing partner of Columbus VP, will join the Integra Therapeutics board of directors.
Co-founded by Marc Güell and Avencia Sánchez-Mejías, Integra is advancing a pgene writing platform to make advanced therapies safer and effective at preventing and treating genetic diseases and cancers with unmet medical needs.
The company intends to use the new funds for the development of the FiCAT platform prototype and preclinical validation with in vivo and ex vivo models.